Korean Industry Bid For Stem Cell Study Simplification Rejected
This article was originally published in PharmAsia News
Executive Summary
South Korea’s Ministry of Food and Drug Safety has rejected a biotechnology industry demand to simplify the process to collect information on the safety and efficacy of stem cell therapies during clinical usage. From July, stem cell therapy companies will be obliged to conduct complete surveys on all patients who receive the therapies.